Dual neurohormonal intervention in CV disease: angiotensin receptor and Neprilysin inhibition.

Abstract:

INTRODUCTION:Cardiovascular disease is the leading cause of death worldwide, accounting for 30% of all deaths, with elevated blood pressure probably the most important modifiable risk factor. Worldwide, elevated blood pressure is estimated to cause 7.5 million deaths, about 12.8% of the total of all annual deaths. New drugs with different efficacy and effectiveness to control cardiovascular and renal disease are always welcomed. AREAS COVERED:Adequate control of arterial hypertension is needed in order to reduce the consequences of cardiovascular and renal disease. A novel compound, LCZ696 , is currently in development based on the concept of comprising in the same entity a Neprilysin inhibitor, with a renin-angiotensin-aldosterone system inhibitor, in this case an angiotensin receptor blocker. This review, performed in PubMed including the last five years under the keywords cited below, presents the available data about LCZ696, the first-in-class angiotensin receptor Neprilysin inhibitor. EXPERT OPINION:Available data show that positive efficacy and a good tolerability profile of LCZ696 in the treatment of arterial hypertension as well as preliminary data indicate that it can also be useful in the treatment of cardiovascular disease. These data are particularly promising in the treatment of arterial hypertension.

authors

Segura J,Salazar J,Ruilope LM

doi

10.1517/13543784.2013.797962

subject

Has Abstract

pub_date

2013-07-01 00:00:00

pages

915-25

issue

7

eissn

1354-3784

issn

1744-7658

journal_volume

22

pub_type

杂志文章,评审
  • Current drugs and medical treatment algorithms in the management of acute decompensated heart failure.

    abstract:BACKGROUND:Acute decompensated heart failure (ADHF) is associated with increased hospitalization rates and high in-hospital mortality, and has emerged as a major public health problem over the past decade. In recent years, several new drugs and therapeutic approaches have failed to reduce short- and long-term morbidity...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543780902922660

    authors: Triposkiadis F,Parissis JT,Starling RC,Skoularigis J,Louridas G

    更新日期:2009-06-01 00:00:00

  • Lenalidomide for the treatment of B-cell lymphoma.

    abstract:INTRODUCTION:Although the combination of an anti-CD20 monoclonal antibody and chemotherapy has widely improved survival of patients with B-cell lymphoma, the disease still relapses. A better understanding of the biology of lymphomas has highlighted the role of the cell of origin in response to treatment and outcome. Le...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1080/13543784.2016.1208170

    authors: Garciaz S,Coso D,Schiano de Colella JM,Bouabdallah R

    更新日期:2016-09-01 00:00:00

  • The therapeutic potential of the cannabinoids in neuroprotection.

    abstract::After thousands of years of interest the last few decades have seen a huge increase in our knowledge of the cannabinoids and their mode of action. Their potential as medical therapeutics has long been known. However, very real concerns over their safety and efficacy have lead to caution and suspicion when applying the...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.11.10.1365

    authors: Grundy RI

    更新日期:2002-10-01 00:00:00

  • Therapeutic peptides for the treatment of systemic lupus erythematosus: a place in therapy.

    abstract:INTRODUCTION:Studies in vitro and in vivo have identified several peptides that are potentially useful in treating systemic lupus erythematosus (SLE). The rationale for their use lies in the cost-effective production, high potency, target selectivity, low toxicity, and a peculiar mechanism of action that is mainly base...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1080/13543784.2020.1777983

    authors: Talotta R,Atzeni F,Laska MJ

    更新日期:2020-08-01 00:00:00

  • An array of immunotherapeutic strategies for B-cell lymphomas.

    abstract::With FDA approval of monoclonal antibodies (mAb) against the B-cell-specific cell surface molecule CD20, immunotherapy in B-cell non-Hodgkin's-lymphomas (NHL) has gained momentum. Since the first description of the CD20 mAb and its use in a single patient, it has taken more than 20 years to implement this in current t...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.8.12.2059

    authors: Schultze JL

    更新日期:1999-12-01 00:00:00

  • Regorafenib for cancer.

    abstract:INTRODUCTION:Regorafenib (BAY 73-4506) is a novel, orally active, diphenylurea multikinase inhibitor of VEGFR1-3, c-KIT, TIE-2, PDGFR-β, FGFR-1, RET, RAF-1, BRAF and p38 MAP kinase. AREAS COVERED:This review covers the preclinical development of regorafenib as well as the pivotal Phase I studies. The safety profile of...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2012.684752

    authors: Strumberg D,Schultheis B

    更新日期:2012-06-01 00:00:00

  • William Harvey Research Conference on PDE inhibitors: drugs with an expanding range of therapeutic uses.

    abstract::Presentations at the William Harvey Research Conference on PDE Inhibitors described the molecular biology, biochemical regulation. pharmacology, and therapeutic utility of inhibitors of cyclic nucleotide phosphodiesterases (PDEs). Most of the talks focused on PDE4 and PDE5. two members of the 11-member PDE family that...

    journal_title:Expert opinion on investigational drugs

    pub_type:

    doi:10.1517/13543784.9.3.621

    authors: O'Donnell

    更新日期:2000-03-01 00:00:00

  • Safely slowing down the decline in Alzheimer's disease: gene therapy shows potential.

    abstract::The role of nerve growth factor in stimulating cholinergic function, loss of which is a cardinal feature in Alzheimer's disease, has been documented for many years from preclinical animal model studies. This anabolic growth factor has been delivered into the forebrain of patients with mild Alzheimer's disease using tr...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.14.7.913

    authors: Braddock M

    更新日期:2005-07-01 00:00:00

  • Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer.

    abstract:INTRODUCTION:EGFR has been implicated in various malignancies such as NSCLC, breast, head and neck, and pancreatic cancer. Numerous drugs have been developed in order to target the tyrosine domain of EGFR as an approach in cancer treatment. AREAS COVERED:This article focuses on the different generations of EGFR tyrosi...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2014.928283

    authors: Lee CC,Shiao HY,Wang WC,Hsieh HP

    更新日期:2014-10-01 00:00:00

  • Skin substitutes to enhance wound healing.

    abstract::Biologically-based skin substitutes have developed as commercial products over the last 5 years. The first generation includes the collagen-based synthetic device, Integra, and Alloderm, which is based on devitalised and cross-linked human dermis. These are used as dermal replacements for third degree burns. Within th...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.7.5.803

    authors: Mansbridge J

    更新日期:1998-05-01 00:00:00

  • Ticagrelor for the treatment of peripheral arterial disease.

    abstract:INTRODUCTION:Peripheral arterial disease (PAD) is a manifestation, and marker of severity, of a generalized atherosclerotic process. Antiplatelet therapy is recommended to prevent cardiovascular events but much of the evidence to support this is drawn from studies on older drugs. AREAS COVERED:In this review, the auth...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2014.974803

    authors: Chong AY,So DY

    更新日期:2014-12-01 00:00:00

  • Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions.

    abstract:INTRODUCTION:Heat shock protein 90 (HSP90) serves as a critical facilitator for oncogene addiction. There has been augmenting enthusiasm in pursuing HSP90 as an anticancer strategy. In fact, since the initial serendipitous discovery that geldanamycin (GM) inhibits HSP90, the field has rapidly moved from proof-of-concep...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2014.902442

    authors: Jhaveri K,Ochiana SO,Dunphy MP,Gerecitano JF,Corben AD,Peter RI,Janjigian YY,Gomes-DaGama EM,Koren J 3rd,Modi S,Chiosis G

    更新日期:2014-05-01 00:00:00

  • New therapeutic perspectives with clevidipine: an ultra-short-acting intravenous Ca2+ channel blocker.

    abstract::Intravenous antihypertensive agents are used in clinical situations in which the immediate, precise control of blood pressure is a clinical necessity. Clevidipine is a new, vascular-selective, dihyrdopyridine Ca(2+) channel blocker, which exerts its hemodynamic effects through selective arterial vasodilation without e...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.16.9.1449

    authors: Gradman AH,Vivas Y

    更新日期:2007-09-01 00:00:00

  • IL-5: biology and potential therapeutic applications.

    abstract::IL-5 is the predominant cytokine associated with antigen-induced eosinophilic inflammation in the lung. The activation of Th-2 cells leads to the production of IL-5. The pro-eosinophilic effects of IL-5 include: (1) enhanced replication and differentiation of eosinophilic myelocytes; (2) enhanced degranulation of eosi...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.9.3.491

    authors: Weltman JK,Karim AS

    更新日期:2000-03-01 00:00:00

  • Identification of heptapeptides interacting with IFN-α-sensitive CML cells.

    abstract:BACKGROUND:Interferon-alpha (IFN-α) is the traditional therapeutic agent for chronic myeloid leukemia (CML). The molecular mechanism of IFN-α efficacy in the treatment of CML is not fully clear. OBJECTIVES:To identify the peptides and/or proteins that bind to the proteins specifically expressed on the surface of IFN-α...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.2011.632407

    authors: Liu J,Chen HC,Rao ZZ,Khan MA,Wan XX,Xu AH,Zhang N,Zhang DZ

    更新日期:2011-12-01 00:00:00

  • Doripenem: an expected arrival in the treatment of infections caused by multidrug-resistant Gram-negative pathogens.

    abstract:BACKGROUND:Potent new drugs against multidrug-resistant Gram-negative bacteria, namely Pseudomonas aeruginosa and Acinetobacter spp. and pan-drug-resistant Klebsiella pneumoniae, which constitute an increasing medical threat, are almost absent from the future pharmaceutical pipeline. OBJECTIVE:This drug evaluation foc...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.17.5.749

    authors: Poulakou G,Giamarellou H

    更新日期:2008-05-01 00:00:00

  • Recent and ongoing clinical trials for treating colorectal cancer.

    abstract::Colorectal cancer is one of the most common cancers worldwide. Through well-designed clinical trials, advances have been made in the treatment of localised and advanced colorectal cancer. It has been established that 6 months of 5-fluorouracil-based chemotherapy will improve overall survival in patients with stage III...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.11.6.871

    authors: Mulcahy MF,Benson AB 3rd

    更新日期:2002-06-01 00:00:00

  • Trends in pioglitazone use among U.S. adults with type 2 diabetes and suspected nonalcoholic fatty liver disease.

    abstract::Background: We aimed to estimate population-based trends in the prevalence of coexisting type 2 diabetes (T2D) and suspected nonalcoholic fatty liver disease (NAFLD) and pioglitazone use among U.S. adults.Research design and methods: We conducted a cross-sectional analysis of the National Health and Nutrition Examinat...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1080/13543784.2020.1704731

    authors: Le P,Chaitoff A,Rothberg MB,McCullough A,Alkhouri N

    更新日期:2020-02-01 00:00:00

  • Investigational platelet-derived growth factor receptor kinase inhibitors in breast cancer therapy.

    abstract:INTRODUCTION:Aberrant regulation of platelet-derived growth factors (PDGFs) and their receptors (PDGFR) has been shown to be involved in many solid tumors, including breast cancer. PDGFR-α and PDGFR-β expressions were documented in breast cancer and are correlated with tumor aggressiveness and metastasis. Preclinical e...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2014.895323

    authors: Criscitiello C,Gelao L,Viale G,Esposito A,Curigliano G

    更新日期:2014-05-01 00:00:00

  • Newer antibacterial drugs for a new century.

    abstract:IMPORTANCE OF THE FIELD:Antibacterial drug discovery and development has slowed considerably in recent years, with novel classes discovered decades ago and regulatory approvals tougher to get. Traditional approaches and the newer genomic mining approaches have not yielded novel classes of antibacterial compounds. Inste...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543780903505092

    authors: Devasahayam G,Scheld WM,Hoffman PS

    更新日期:2010-02-01 00:00:00

  • IBC's 5th Annual Conference on Blood Substitutes.

    abstract::IBC's 5(th) Annual Conference on Blood Substitutes was held on November 20-21, 1997. Approximately 100 medical researchers, academic scientists, blood substitute company speakers and representatives from major pharmaceutical companies with an interest or partner in the field attended. The papers presented focused on t...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.7.2.283

    authors: Shorr RG

    更新日期:1998-02-01 00:00:00

  • Investigational vasopressin receptor modulators in the pipeline.

    abstract::The vasopressin system is complex and interacts with the central nervous, cardiovascular, renal, and hematological systems. Vasopressin plays an important role in the control of blood osmolarity and vascular tone, but is also involved in many other physiological events, which are mediated mainly via three types of vas...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543780903066764

    authors: Favory R,Salgado DR,Vincent JL

    更新日期:2009-08-01 00:00:00

  • Aromatase inhibitors for the treatment of infertility.

    abstract::Ovarian stimulation during infertility treatment is used either alone or in conjunction with intrauterine insemination and assisted reproductive technologies. At the present time, the two main medications used for ovarian stimulation include an oral antioestrogen, clomiphene citrate and injectable gonadotrophins. In s...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.12.3.353

    authors: Mitwally MF,Casper RF

    更新日期:2003-03-01 00:00:00

  • Current status and future development of antitubercular chemotherapy.

    abstract::Tuberculosis (TB), which kills more people than any other infectious disease, was declared a global emergency by the World Health Organization in 1993. The emergence of new Mycobacterium tuberculosis strains that are resistant to some or all current antitubercular drugs seriously hampers the control of the disease. Up...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.11.8.1033

    authors: Kremer LS,Besra GS

    更新日期:2002-08-01 00:00:00

  • Investigations on gossypol: past and present developments.

    abstract::Gossypol has received significant attention as a result of its potential therapeutic application as a male antifertility agent. Furthermore, recent research examining the biological activity of gossypol has revealed a number of other promising lines of enquiry. These have focused on the antitumour, antiviral and antio...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.14.11.1419

    authors: Dodou K,Anderson RJ,Small DA,Groundwater PW

    更新日期:2005-11-01 00:00:00

  • Current Role of Dacomitinib in Head and Neck Cancer.

    abstract:INTRODUCTION:Recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) has a dismal prognosis. With the emergence of monoclonal antibodies and tyrosine kinase inhibitors (TKI) targeting the epidermal growth factor receptor (EGFR), several drugs were developed and tested in HNSCC. To date, the monoclonal...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1080/13543784.2016.1177022

    authors: Elicin O,Ozsahin M

    更新日期:2016-06-01 00:00:00

  • Recombinant TFPI and variants: potential implications in the treatment of cardiovascular disorders.

    abstract::The Kunitz-type proteinase inhibitor, tissue factor pathway inhibitor (TFPI), is the only endogenous inhibitor of the tissue factor (TF)-mediated coagulation pathway that plays a dominant role in normal haemostasis. TFPI exerts its action by binding to factor Xa (FXa) forming a TFPI-FXa complex that then, in a second ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.7.7.1121

    authors: Kaiser B,Hoppensteadt DH,Fareed J

    更新日期:1998-07-01 00:00:00

  • The therapeutic effects of vitamin D3 and its analogues in psoriasis.

    abstract::Psoriasis is a common skin disease which is characterised by the proliferation and abnormal differentiation of keratinocytes, coupled with complex immune disturbances. The beneficial effects of vitamin D derivatives in this disease are due to their capacity to inhibit proliferation, their ability to induce normal diff...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.7.1.77

    authors: Guilhou JJ

    更新日期:1998-01-01 00:00:00

  • Recombinant toxins in haematologic malignancies and solid tumours.

    abstract::Recombinant toxins constitute a new modality for the treatment of cancer, since they target cells displaying specific surface-receptors or antigens. They are fusion proteins, which contain toxin and ligand regions, and are produced in Escherichia coli. The ligand may be a growth factor or a fragment of an antibody, an...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.7.9.1405

    authors: Kreitman RJ

    更新日期:1998-09-01 00:00:00

  • Armodafinil: a new treatment for excessive sleepiness.

    abstract:BACKGROUND:Armodafinil is a wake-promoting agent developed by Cephalon that was approved in mid-2007 for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea and shift work disorder. It is the R-enantiomer of the compound modafinil. Like modafinil, the mechanism of action for armoda...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.17.4.565

    authors: Lankford DA

    更新日期:2008-04-01 00:00:00